2025
47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers
Schickler M, Mercade T, Cecchini M, Garcia-Carbonero R, Golan T, Perets R, Borazanci E, Trujillo M, Ponz M, Al-Hallak M, Pant S, Boni V, Saavedra O, De Miguel M, Leal A, Martin A, Nadal T, David H, Reuveni H. 47P Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers. ESMO Open 2025, 10: 104206. DOI: 10.1016/j.esmoop.2025.104206.Peer-Reviewed Original ResearchEVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH).
Spencer K, Punekar S, Grierson P, Mitchell J, Lin Y, Biachi de Castria T, Zhen D, Vu P, Morelli M, Kundranda M, Dorigo O, Maloney D, Ward J, Eng C, Maus M, Simeone D, Welch J, Molina J, Go W, Hecht J. EVEREST-2: A seamless phase 1/2 study of A2B694, a logic-gated Tmod chimeric antigen receptor T-cell (CAR T) therapy, in patients with pancreatic cancer (PANC) or other mesothelin (MSLN)-expressing solid tumors and human leukocyte antigen (HLA)–A*02 loss of heterozygosity (LOH). Journal Of Clinical Oncology 2025, 43: tps788-tps788. DOI: 10.1200/jco.2025.43.4_suppl.tps788.Peer-Reviewed Original ResearchOff-tumor toxicityCAR-T therapyPancreatic cancerHLA-A*02T cellsSolid tumorsCAR-TT therapyNormal cellsChimeric antigen receptor T cellsRecommended phase 2 doseT cell receptor therapyNon-small cell lungCryopreserved T cellsPhase 2 doseDose-expansion phaseProgression-free survivalTumor-associated antigensCAR-T activityObjective of Phase 1First-in-humanOverall response rateOn-targetDose escalationMSLN expressionComprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas
Antony V, Sun T, Dolezal D, Cai G. Comprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas. Cancers 2025, 17: 335. PMID: 39941707, PMCID: PMC11815932, DOI: 10.3390/cancers17030335.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaPrimary pancreatic ductal adenocarcinomaMolecular profilingGene mutationsGene copy number alterationsAdvanced-stage pancreatic cancerInsufficient tumor cellsOncomine Comprehensive AssayRate of TP53Copy number alterationsMetastatic diseasePDAC casesPIK3CA mutationsPancreatic cancerPoor prognosisTreatment optionsDuctal adenocarcinomaTumor cellsTumor progressionMolecular alterationsStudy cohortMolecular testingComprehensive assayTherapeutic targetPractices and perspectives of genetic counselors about high‐risk pancreatic cancer screening: A cross‐sectional survey study
Wiegand A, Chhoda A, Namboodiri A, Grimshaw A, Dalela D, Farrell J. Practices and perspectives of genetic counselors about high‐risk pancreatic cancer screening: A cross‐sectional survey study. Journal Of Genetic Counseling 2025, 34: e2016. PMID: 39814542, DOI: 10.1002/jgc4.2016.Peer-Reviewed Original ResearchConceptsCancer screening programHigher risk of pancreatic cancerPancreatic cancer screeningPancreatic cancer screening programsHigh-risk individualsGenetic counselorsCancer screeningScreening programReferral of high-risk individualsPerspectives of genetic counselorsCancer genetic counselorsCross-sectional survey studyIncrease provider comfortGenetic counseling programsIdentification of high-risk individualsPancreatic cancerConsensus guidelinesProvider comfortPancreas ScreeningExpert consensus guidelinesIdeal providersIdentification of individualsSurveillance of individualsCounseling individualsReferral
2024
Per- and poly-fluoroalkyl substances exposure and risk of gastrointestinal cancers: a systematic review and meta-analysis.
Zhang S, Kappil E, Zheng T, Boffetta P, Seyyedsalehi M. Per- and poly-fluoroalkyl substances exposure and risk of gastrointestinal cancers: a systematic review and meta-analysis. European Journal Of Cancer Prevention 2024 PMID: 39648934, DOI: 10.1097/cej.0000000000000935.Peer-Reviewed Original ResearchPFAS exposureStratified analysisMeta-analysisRisk of gastrointestinal cancerSystematic reviewGastrointestinal cancerModified Newcastle-Ottawa ScaleInternational Agency for Research on Cancer MonographsNewcastle-Ottawa ScaleSystematic review of literatureDose-response trendRandom-effects modelPancreatic cancerPotential confoundersIndependent reviewersYear of publicationPublication biasStudy designMeta-analysesColorectal cancerGastric cancerQuality scoresColorectalSubstance exposurePoly-fluoroalkyl substancesPalliative Care and End-of-Life Care in Metastatic Pancreatic Cancer
O’Brien J, Halsey B, Connors M, Deng M, Handorf E, Berardi G, Lynch S, Sorice K, Reddy S, Meyer J, Bauman J, Dotan E. Palliative Care and End-of-Life Care in Metastatic Pancreatic Cancer. Journal Of Palliative Medicine 2024, 28: 217-223. PMID: 39636708, DOI: 10.1089/jpm.2024.0313.Peer-Reviewed Original ResearchEnd of lifeAggressive EOL carePalliative careDay of deathEOL carePC consultationIntegration of palliative careEnd of life careEnd-of-life careAssociated with worse qualityHealth care resourcesMetastatic pancreatic cancerQuality of lifePC teamAggressive careCare resourcesHospiceAverage length of timeTertiary cancer centerCareWorse qualityAverage timeCancer CenterBenefit patientsPancreatic cancerThe PRECEDE consortium: A longitudinal international cohort study of high-risk individuals for the development of pancreatic cancer
Earl J, Zogopoulos G, Bi Y, Brand R, Chung D, Farrell J, Graf J, Kastrinos F, Katona B, Klute K, Koptiuch C, Kupfer S, Kwon R, Lindberg J, Lowy A, Lucas A, Paiella S, Paiella S, Permuth J, Rosie C, Simeone D. The PRECEDE consortium: A longitudinal international cohort study of high-risk individuals for the development of pancreatic cancer. Pancreatology 2024, 24: e82-e83. DOI: 10.1016/j.pan.2024.05.206.Peer-Reviewed Original ResearchS98 Intratumoral Microbiome Associations With the Infiltration of Natural Killer Cells and Improved Patient Survival in Pancreatic Cancer
Bizyayev D, Merchant A, Segarra D, Montano M, Shahin A, Challa P, Avila C, Al-Zakwani M, Zaman S. S98 Intratumoral Microbiome Associations With the Infiltration of Natural Killer Cells and Improved Patient Survival in Pancreatic Cancer. The American Journal Of Gastroenterology 2024, 119: s71-s71. DOI: 10.14309/01.ajg.0001028760.53866.e7.Peer-Reviewed Original ResearchKeep It Moving: Physical Activity in the Prevention of Obesity-Driven Pancreatic Cancer.
Sogunro A, Muzumdar M. Keep It Moving: Physical Activity in the Prevention of Obesity-Driven Pancreatic Cancer. Cancer Research 2024, 84: 2935-2937. PMID: 39279380, DOI: 10.1158/0008-5472.can-24-1474.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTumor microenvironmentAntitumor effectPancreatic cancerObese micePhysical activityAdvanced tumor growthSystemic cytokine productionMyeloid cell infiltrationPancreatic ductal adenocarcinoma developmentEffect of obesityHigh-fat diet-induced obesityDiet-induced obesitySyngeneic allograftsAdvanced tumorsProtumorigenic effectsLean miceWhite adipose tissueCell infiltrationDuctal adenocarcinomaObesity-associatedTumor growthCytokine productionImpact of physical activityInflammatory cytokinesOmission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.
Peng C, Saffo S, Oberstein P, Shusterman M, Thomas C, Becker D, Berlin J, Leichman L, Boursi B, Nagar A, Yu S. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal Of The National Comprehensive Cancer Network 2024, 22: 521-527. PMID: 39236754, DOI: 10.6004/jnccn.2024.7029.Peer-Reviewed Original ResearchMultidrug regimensFOLFIRINOX regimensAdvanced colorectalGastrointestinal cancerAssociated with decreased survivalGranulocyte colony-stimulating factorCompare survival outcomesGastrointestinal cancer treatmentBaseline clinical factorsKaplan-Meier analysisFirst-line FOLFOXMulticenter cohort studyColony-stimulating factorInverse probability of treatmentAdvanced gastrointestinal cancerTreatment selection biasProbability of treatmentHealth care savingsCox proportional hazardsOverall survivalEffective regimenIPTW analysisSurvival outcomesPancreatic cancerAssociated with reductionsDeep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer
Kim S, Kim S, Kim E, Cecchini M, Park M, Choi J, Kim S, Hwang H, Kang C, Choi H, Shin S, Kang J, Lee C. Deep-Transfer-Learning–Based Natural Language Processing of Serial Free-Text Computed Tomography Reports for Predicting Survival of Patients With Pancreatic Cancer. JCO Clinical Cancer Informatics 2024, 8: e2400021. PMID: 39151114, DOI: 10.1200/cci.24.00021.Peer-Reviewed Original ResearchConceptsArea under the receiver operating characteristic curveSurvival of patientsCT reportsPancreatic cancerNatural language processingC-indexPredicting survivalOverall survival of patientsTertiary hospitalPredicting 1-year survivalPredicting survival of patientsImproved C-indexSurvival informationPancreatic cancer survivalReceiver operating characteristic curveInternal test data setNLP modelsComputed tomography reportsLanguage processingKorean tertiary hospitalOverall survivalConsecutive patientsActual survivalConcordance indexPatientsThe mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review
Dunne R, Crawford J, Smoyer K, McRae T, Rossulek M, Revkin J, Tarasenko L, Bonomi P. The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review. Journal Of Cachexia Sarcopenia And Muscle 2024, 15: 1628-1640. PMID: 39095951, PMCID: PMC11446707, DOI: 10.1002/jcsm.13510.Peer-Reviewed Original ResearchWeight loss categoriesSystematic literature reviewPancreatic cancerColorectal cancerAssessment of weight changeStatistically significant poorer survivalLoss categoriesUnintentional weight lossRisk of cachexiaWeight lossPoor survivalInternational consensusAssociated with significantly poorer survivalMortality burdenLiterature reviewEligibility criteriaPRISMA guidelinesCancer-associated cachexiaColorectalProgressive functional impairmentClinical practiceFunctional impairmentWasting disordersPoor prognosisWeight changeGenome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk.
Ni Z, Kundu P, McKean D, Wheeler W, Albanes D, Andreotti G, Antwi S, Arslan A, Bamlet W, Beane-Freeman L, Berndt S, Bracci P, Brennan P, Buring J, Chanock S, Gallinger S, Gaziano J, Giles G, Giovannucci E, Goggins M, Goodman P, Haiman C, Hassan M, Holly E, Hung R, Katzke V, Kooperberg C, Kraft P, LeMarchand L, Li D, McCullough M, Milne R, Moore S, Neale R, Oberg A, Patel A, Peters U, Rabe K, Risch H, Shu X, Smith-Byrne K, Visvanathan K, Wactawski-Wende J, White E, Wolpin B, Yu H, Zeleniuch-Jacquotte A, Zheng W, Zhong J, Amundadottir L, Stolzenberg-Solomon R, Klein A. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers & Prevention 2024, 33: 1229-1239. PMID: 38869494, PMCID: PMC11928872, DOI: 10.1158/1055-9965.epi-24-0096.Peer-Reviewed Original ResearchConceptsPancreatic cancer riskHeavy alcohol consumptionCancer riskSingle-nucleotide polymorphismsAlcohol consumptionExpression quantitative trait lociQuantitative trait lociAssociated with pancreatic cancer riskGenome-wide interaction analysisGenome-wide significant evidenceEtiology of pancreatic cancerFixed-effect meta-analysesGenomic regionsGenome-wide significant evidence of associationLead single-nucleotide polymorphismsTrait lociGenetic variantsEuropean ancestry populationsEvidence of associationGenome-wide association studiesAnalysis of single-nucleotide polymorphismsCase-control studyPancreatic cancerGenome-wide analysisAncestry populationsTrastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).
Oh D, Lugowska I, Stroyakovskiy D, Jung K, Dumas O, Penkov K, Dechaphunkul A, Oaknin A, Kim S, Starling N, Chewaskulyong B, Charonpongsuntorn C, Doroshow D, Hsiao S, Hung Y, Jung L, Kuptsova-Clarkson N, Michelini F, Puvvada S, Meric-Bernstam F. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Journal Of Clinical Oncology 2024, 42: 4090-4090. DOI: 10.1200/jco.2024.42.16_suppl.4090.Peer-Reviewed Original ResearchBiliary tract cancerProgression-free survivalT-DXdPancreatic cancerHER2 expressionEfficacy outcomesDrug-related interstitial lung diseaseOpen-label phase 2 studyPC cohortDrug-related adverse eventsLate-line treatmentPrimary tumor locationPhase 2 studyGrade (GClinically meaningful benefitInterstitial lung diseaseHER2-expressing tumorsAdvanced/metastatic diseaseData cutoffIHC 3PD-L1Trastuzumab deruxtecanExploratory endpointsTumor locationPrimary endpointReview of the cost-effectiveness of surveillance for hereditary pancreatic cancer
Wang L, Levinson R, Mezzacappa C, Katona B. Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. Familial Cancer 2024, 23: 351-360. PMID: 38795221, PMCID: PMC11255025, DOI: 10.1007/s10689-024-00392-1.Peer-Reviewed Original ResearchHigh-risk individualsHereditary pancreatic cancerSusceptibility to pancreatic cancerPancreatic cancer riskFamily history of PCSurveillance strategiesPancreatic cancerCost-effectiveness of surveillanceHistory of PCCost-effectiveness studiesCost-effectiveCancer riskCost-effectiveness analysisPancreatic surveillanceHigh-risk groupOptimal surveillance strategyFamily historyNew-onset diabetesRisk individualsSporadic PCHealth benefitsPotential health benefitsPC diagnosisSub-groupsSurveillanceDevelopment and Validation of Case-Finding Algorithms to Identify Pancreatic Cancer in the Veterans Health Administration
Mezzacappa C, Larki N, Skanderson M, Park L, Brandt C, Hauser R, Justice A, Yang Y, Wang L. Development and Validation of Case-Finding Algorithms to Identify Pancreatic Cancer in the Veterans Health Administration. Digestive Diseases And Sciences 2024, 69: 1507-1513. PMID: 38453743, DOI: 10.1007/s10620-024-08324-w.Peer-Reviewed Original ResearchElectronic health recordsVeterans Health AdministrationHealth AdministrationElectronic health records data elementsElectronic health record dataDiagnosis of exocrine pancreatic cancerNational Cancer RegistryCancer RegistryHealth recordsExocrine pancreatic cancerOncology settingOutpatient encountersInpatient encountersData elementsExpert adjudicationPancreatic ductal adenocarcinomaEpidemiological studiesRandom sampleInterquartile rangeIdentification of patientsRange of patientsPancreatic cancerVeteransLate diagnosisExcellent PPVEfficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial
Guo X, Lou W, Xu Y, Zhuang R, Yao L, Wu J, Fu D, Zhang J, Liu J, Rong Y, Jin D, Wu W, Xu X, Ji Y, Wu L, Lv M, Yao X, Liu X, Wang D, Kuang T, Liu L, Wang W, Liu T, Zhou Y. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Oncology Letters 2024, 27: 161. PMID: 38449794, PMCID: PMC10915801, DOI: 10.3892/ol.2024.14293.Peer-Reviewed Original ResearchProgression-free survivalAdvanced pancreatic cancerC-reactive proteinPancreatic cancerAS regimenNab-paclitaxelAdvanced PCPrimary endpointGene mutationsEfficacy of nab-paclitaxelPatients treated with GSSafety of nab-paclitaxelMedian progression-free survivalMedian follow-up timePhase II randomized trialC-reactive protein levelsHigh C-reactive proteinImproved overall survivalSubsets of patientsFollow-up timeCost-effective treatment regimenOS benefitData cutoffOpen-labelOverall survivalIncorporating stereotactic body radiation therapy for inoperable pancreatic cancer.
Lukez A, Hasler J, Reddy S, Dotan E, Astsaturov I, Lynch S, Sorice K, Meyer J. Incorporating stereotactic body radiation therapy for inoperable pancreatic cancer. Journal Of Clinical Oncology 2024, 42: 656-656. DOI: 10.1200/jco.2024.42.3_suppl.656.Peer-Reviewed Original ResearchStereotactic body radiation therapyStereotactic body radiation therapy groupYear of diagnosisInoperable pancreatic cancerInoperable PCLocal progressionPancreatic cancerRadiation therapyIncreasing year of diagnosisSingle-institution retrospective reviewYounger age of diagnosisCumulative incidence functionMedian SBRT dosePrimary tumor growthFine-Gray regression modelsSubgroup of patientsMedian year of diagnosisAge of diagnosisPercutaneous endoscopic gastrostomy tubeSBRT doseMetastatic casesMetastatic PCObstructive symptomsRetrospective reviewMedian time
2023
Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials
Rosen E, Schonhoft J, Silverman I, Yablonovitch A, Sethuraman S, Nejad P, Ulanet D, Yang J, Kim I, Fei K, Xu Y, Lagow E, Zhang S, Cai M, Koehler M, Carneiro B, Lheureux S, Cecchini M, Herzberg B, Reis-Filho J, Rimkunas V, Yap T. Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials. Molecular Cancer Therapeutics 2023, 22: a123-a123. DOI: 10.1158/1535-7163.targ-23-a123.Peer-Reviewed Original ResearchCirculating tumor DNAVariant allele frequencyDNA damage repairEpigenomic profilingTumor DNADamage repairResponse monitoringCirculating tumor DNA sequencingLow variant allele frequencyTreated with PARPiPhase 1 studyCell-free DNAMolecular responseIntragenic deletionsEpigenetic analysisAllele frequenciesRad3-relatedCH variantsGenomic alterationsOn-treatmentClinical outcomesPancreatic cancerAtaxia telangiectasiaPathogenic alterationsEvaluable ptsEmerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review
Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert P, Harari P, Rimm D, Burtness B, Kuhar C, Carchman E. Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review. Viruses 2023, 15: 2320. PMID: 38140561, PMCID: PMC10748233, DOI: 10.3390/v15122320.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaTriple-negative breast cancerCancer typesPredictive significancePrognostic factorsClinical outcomesPrognostic significanceCell carcinomaHuman cancersCervical squamous cell carcinomaNeck squamous cell carcinomaAvailable clinical evidenceCochrane Central RegisterInferior clinical outcomesPositive prognostic factorNegative predictive factorNegative prognostic factorWeb of ScienceCentral RegisterControlled TrialsCervical cancerClinical evidencePredictive factorsPancreatic cancerEligible studies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply